Latest news with #PCRX
Yahoo
09-04-2025
- Business
- Yahoo
Pacira price target raised to $28 from $25 at Truist
Truist analyst Les Sulewski raised the firm's price target on Pacira (PCRX) to $28 from $25 and keeps a Hold rating on the shares. The firm cites a settlement with eVenus and counterparts for their generic entry of bupivacaine liposome injectable suspension – gExparel – and now envision peak Exparel sales of $740M by 2029, the analyst tells investors in a research note. The deal also removes the much debated overhang, Truist adds. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on PCRX: Disclaimer & DisclosureReport an Issue Positive Outlook for Pacira Pharmaceuticals Amid Exparel Settlement and Strategic Growth Initiatives Pacira price target raised to $26 from $22 at RBC Capital Pacira price target raised to $65 from $48 at H.C. Wainwright Closing Bell Movers: Levi Strauss up 8% on earnings, futures find footing Pacira Pharmaceuticals Settles Patent Litigation with Fresenius Sign in to access your portfolio
Associated Press
07-03-2025
- Business
- Associated Press
Shareholders that lost money on Pacira BioSciences, Inc. PCRX) should contact Levi & Korsinsky about pending Class Action
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ('Pacira' or the 'Company') (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team: PCRX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court 'found that the company's U.S. Patent No. 11,033,495 (the '495 patent) is not valid,' and, thus, eVenus is not infringing on anything. Pacira's '495 patent is for Exparel, which is the main source of growth for the Company, encapsulating roughly 80% of its revenue. Analysts have noted that the invalidity of the '495 patent calls into question the validity of the Company's other patents, potentially resulting in more generic entrants into the market and increased litigation expenses moving forward. Following this news, Pacira's common stock declined dramatically. From a closing market price of $22.36 per share on August 8, 2024, Pacira's stock price fell to a low of $11.70 per share on August 9, 2024, a decline of over 47% in a single day. WHAT'S NEXT? If you suffered a loss in Pacira during the relevant time frame, you have until March 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004
Associated Press
07-03-2025
- Business
- Associated Press
PCRX FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - March 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the 'Class Period'), of the important March 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Pacira class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 14, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, statements made during the Class Period were false and/or misleading because defendants created the false impression that Pacira had sufficient patent protections on Exparel and, as such, the ability to expand the marketing, production, and sales of Exparel, which Pacira stated was critical to its future growth and revenue. In truth, Pacira's optimistic claims pertaining to its patent protections on Exparel were fragile at best. In fact, Pacira knew that the '495 patent was not as protective as defendants publicly touted because on June 6, 2023 the New Jersey District Court issued a ruling in eVenus's favor regarding claims construction in another case filed by Pacira in a failed attempt to protect Exparel. Yet defendants continued to make public statements affirming their belief in the '495 patent and the protection it applied for Exparel. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Pacira class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653
